3D Medicines, an oncology aesculapian probe and improvement company, tapped Han Kun Law Firm’s intelligence spot services during preparations for its HKD430 cardinal Hong Kong IPO, to support aggregate patented drugs.
Han Kun said its biomedical and IP squad provided merchandise pipeline freedom-to-operate (FTO) analysis, patent portfolio analysis, IP statement reviews, and reappraisal of the related contented successful company’s prospectus. 3D Medicine debuted connected 15 December 2022.
Envafolimab, 3D Medicine’s halfway product, was commercialised successful December 2021 and the exertion utilized successful the cause allows patients to beryllium injected subcutaneously, offering the convenience of receiving attraction astatine the nearest infirmary oregon adjacent astatine home.
For this merchandise and 11 different candidates, 3D Medicines has established a cancer-drug pipeline from pre-clinical find and objective trials to last marketing.
At present, 3D Medicines has 24 patents and 20 pending patent applications worldwide, portion 10 patents and 10 patent applications for envafolimab are co-owned by the pharmaceutical institution Alphamab Group.
O’Melveny advised 3D Medicines connected Hong Kong and US law, Commerce & Finance Law Firm advised connected PRC law, and Conyers Dill & Pearman provided Cayman Islands ineligible advice.
Business partners Geng Ke and Zhu Ke led the O’Melveny team, with partners Rob Plesnarski and Kurt Berney providing proposal connected taxation issues.
CICC and China Securities International were the associated sponsors, who sought ineligible proposal from Herbert Smith Freehills connected Hong Kong and US, and Zhong Lun Law Firm advised connected PRC law.
Partners Isaac Chen and Wang Zhong led the Herbert Smith Freehills team, with enactment from spouse Jason Sung. Partner Li Jing led the Zhong Lun team.
English (US)